Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.
AffiliationCRC Department Medical Oncology, Christie Hospital, Manchester.
MetadataShow full item record
AbstractA total of 47 poor-risk small-cell lung cancer patients (elderly, poor performance status, recent myocardial infarction, or extensive-stage disease with biochemical abnormalities) were treated with a regimen of bolus ifosfamide at 1.5 g/m2 with equidose mesna as a 30-min infusion, followed by 100 mg oral etoposide daily for 8 days. Therapy was repeated every 3 weeks. The overall response rate was 60% (75% for limited-stage and 48% for extensive-stage disease), and the overall median survival was 7 months. Patients' performance status significantly improved with therapy (P less than 0.0001). Despite the poor-risk factors, the Manchester prognostic score was applied and verified. The median survival was 8 months for patients with a good prognosis, 6 months for those with an intermediate prognosis and 2.5 months for poor-prognosis patients (P = 0.0002). Therapy was well tolerated. The median WHO grade of haematological toxicity was 2 (range, 0-4). Only 10/226 (4%) courses were delayed due to leukopenia. Blood transfusions followed 18/226 (8%) courses. Intravenous antibiotics were given following 15/226 (7%) courses. No patient required platelet support. Poor-risk patients who have a good or intermediate Manchester prognostic score may benefit from this low-toxicity regimen.
CitationTherapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide. 1990, 26 (1):71-4 Cancer Chemother Pharmacol
JournalCancer Chemotherapy and Pharmacology
- Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
- Authors: Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK
- Issue date: 1998 Jan 15
- A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.
- Authors: Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L
- Issue date: 1993 Jun
- Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
- Authors: Skarlos DV, Samantas E, Pectasides D, Pavlidis N, Kalofonos C, Klouvas G, Panoussaki E, Tsiakopoulos E, Poulakis N, Fountzilas G
- Issue date: 1999 Feb
- Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
- Authors: Kamthan AG, Lind MJ, Thatcher N, Steward WP, Bronchud MH, Ranson MR, Stout R
- Issue date: 1990
- A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.
- Authors: Anderson H, Prendiville J, Thatcher N, Radford JA, Swindell R
- Issue date: 1991